Treating chronic graft-versus-host disease with ruxolitinib in both adult and pediatric patients was found to be safe and effective based on data from 2 separate single-center retrospective analyses whose results were presented during a poster session at the 2020 Transplantation & Cellular Therapy Meetings in Orlando, Florida.
Tania Jain, MBBS, discusses the role of ruxolitinib as treatment of graft-versus-host disease.
In an interview with Targeted Oncology, Martin T. King, MD, PhD,discusses INTREPId following his poster presentation of the trial design at the 2020 Genitourinary Cancer Symposium. He also discusses other another promising studies being presented at the conference.
Most patients with metastatic renal cell carcinoma whose disease progresses after immunotherapy given either alone or in combination with other agents receive subsequent treatment with VEGF tyrosine kinase inhibitors or mTOR inhibitors. When administered post-immunotherapy, cabozantinib is associated with superior median progression free survival, according to retrospective data from a real-world study of patients treated at 16 Italian referral centers.
Stereotactic body radiotherapy combined with nivolumab was associated with “high” disease control and overall survival rates in a phase II study of pretreated patients with metastatic renal cell carcinoma, according to lead investigator Cristina Masini, MD, who presented the data at the 2020 Genitourinary Cancers Symposium.
Combining a broad-spectrum tyrosine kinase inhibitor with an immune checkpoint inhibitor resulted in a high disease control rate in a preliminary dose-finding trial involving patients with advanced clear cell renal cell carcinoma.
A fourth of patients with advanced clear cell renal cell carcinoma responded to single-agent therapy with an oral hypoxia-inducible factor–2α inhibitor, which achieved a disease control rate of 80%, a preliminary clinical trial showed.
Nivolumab plus gemcitabine and cisplatin administered in the neoadjuvant setting to patients with muscle-invasive bladder cancer resulted in a pathologic nonmuscle-invasive rate of 66% and a pathologic complete response rate of 49%.
Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, senior physician, instructor in medicine, Harvard Medical School, discusses the goals of the phase III CheckMate-9ER trial, which is evaluating cabozantinib combined with nivolumab in previously untreated patients with advanced or metastatic renal cell carcinoma (RCC).
The combination of durvalumab and olaparib may have activity as neoadjuvant therapy in the treatment of muscle-invasive bladder carcinoma.
Alexandra Drakaki, MD, assistant professor of medicine, hematology, and oncology, University of California, Los Angeles, discusses the goals of the phase Ib/II MORPHEUS trial, which is an umbrella study evaluating several second-line immunotherapy combinations in patients with advanced or metastatic urothelial carcinoma.
Apalutamide plus androgen deprivation therapy reduced the risk of second progression or death regardless of hormonal or taxane therapy as the first subsequent life-prolonging therapy in patients with metastatic castration-sensitive prostate cancer.
Men with metastatic castration-resistant prostate cancer had inferior immune responses with the combination of sipuleucel-T and radium-223 but improved clinical outcomes as compared with sipuleucel-T alone, a small randomized trial showed.
Combining cabozantinib and atezolizumab induced durable responses in men with metastatic castration-resistant prostate cancer who had soft tissue progression after prior hormonal therapy.<br />
Monika Joshi, MD, MRCP, associate professor of medicine, Division of Hematology-Oncology, and co-leader for Genitourinary Disease Team, at Penn State Hershey Cancer Institute, discusses the phase Ib/II results of a trial looking at concurrent durvalumab and radiation therapy followed by adjuvant durvalumab in patients with locally advanced urothelial cancer of the bladder.
Arati Desai, MD, explains how the results from the phase III STELLAR trial will enhance knowledge of anaplastic astrocytoma.
The combination of regorafenib plus an oral fluoropyrimidine, TAS-102, as third-line treatment in patients with metastatic colorectal cancer, achieved a clinically meaningful disease control rate in the phase I dose-escalation trial REMETY, according to data presented at the 2020 Gastrointestinal Cancers Symposium.
Better rates of overall survival were observed in patients with intermediate-stage hepatocellular carcinoma who had an elevated baseline alpha-fetoprotein level when ramucirumab was used as second-line therapy after sorafenib compared with second-line placebo. These improvements occurred irrespective of patients' Barcelona Clinic Liver Cancer stage and were based on results of a pooled analysis of the phase III REACH and REACH-2 trials
Joseph Chao, MD, discusses the importance of assessing the microsatellite instability (MSI) status in patients with advanced gastric/gastroesophageal junction cancer based on findings from a comparative analysis of KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062.
Lenvatinib in combination with nivolumab demonstrated promising antitumor activity in patients with unresectable hepatocellular carcinoma with no new safety signals reported.
Frontline lenvatinib followed by an anticancer procedure resulted in prolonged overall survival in patients with unresectable hepatocellular carcinoma when compared against sorafenib, according to results of a post hoc analysis of the REFLECT trial reported at the 2020 GI Cancers Symposium.
Antitumor activity in patients with germline <em>BRCA/PALB2</em>-mutant pancreatic ductal adenocarcinoma was reported with the chemotherapy doublet of gemcitabine plus cisplatin with or without the addition of veliparib, according to data presented at the 2020 Gastrointestinal Cancers Symposium.
In an interview with Targeted Oncology, Vincent Chung, MD, discussed the findings from the pilot trial evaluating the addition of dietary supplements to combination chemotherapy in patients with unresectable pancreatic cancer. He also highlighted the importance of these findings and the next steps necessary to evaluate the role of supplements in pancreatic cancer further.
Promising antitumor activity with durable responses were demonstrated with the combination of nivolumab and ramucirumab plus paclitaxel in a phase II study of patients with advanced gastric cancer, which wsa presented at the 2020 Gastrointestinal Cancers Symposium. Among patients treated with the combination, the objective response rate was 37.2%, and all responders had a partial response.
The addition of ipilimumab with the combination cabozantinib and nivolumab led to higher response rates, as well as progression-free survival and overall survival in patients with advanced hepatocellular carcinoma compared with the doublet combination alone, according to a presentation at the 2020 GI Cancers Symposium, held January 23-25, in San Francisco, California.
Overall survival was meaningfully improved with treatment of pembrolizumab in first and later lines for patients with advanced gastric/gastroesophageal junction cancer with a high number of PD-L1–expressing cells in the tumor, lymphocytes, and macrophages compared with chemotherapy.
A subset of patients with GI cancers harboring <em>NTRK</em> gene fusions had positive responses to selective TRK inhibition with larotrectinib, confirming efficacy of the agent in this group. The results of the confirmatory trial were recently reported the 2020 Gastrointestinal Cancers Symposium.
In an interview with Targeted Oncology, Kaoru Tsuchiya, MD, discussed the results of the real-world study of lenvatinib in patients with unresectable hepatocellular carcinoma that are being presented at the 2020 Gastrointestinal Cancers Symposium.
Hirva Mamdani, MD, explains the rationale for conducting a safety and efficacy study of durvalumab in patients following multimodality therapy for locally advanced esophageal and gastroesophageal junction adenocarcinoma.
Adam M. Brufsky, MD, PhD, FACP, discusses the TBCRC049 trial, which looks at the safety and efficacy of the tucatinib/trastuzumab/capecitabine combination to treat leptomeningeal metastases in HER2-positive breast cancer.